Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83%
Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.
/ 4 items
#TAK↓
Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1
Twice-daily pill improves wakefulness and reduces symptoms.
A New Dawn for Narcolepsy: Understanding Alixorexton's Promise
Alixorexton, a new drug for narcolepsy type 1, shows great promise. It helps patients stay awake longer (28 mins, considered normal), reduces sleepiness, cataplexy, fatigue, and improves focus. It's well-tolerated and moving to Phase 3, signaling a potential new era for treatment.